Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #CDKL5–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at the Morgan Stanley Virtual Global Healthcare Conference, H.C Wainwright Virtual Global Investment Conference and Cantor Virtual Global Healthcare Conference during the week of September 14.

Additional details can be found below:

H.C. Wainwright Virtual Global Investment Conference

Date: Tuesday, September 15

Time: 12:00 noon Eastern Time

Presenter: Ed Smith, Chief Financial Officer, and Dr. Joseph Hulihan, Chief Medical Officer

Link to webcast: https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=mrns

Morgan Stanley Virtual Global Healthcare Conference

Date: Tuesday, September 15

Time: 1:15 pm Eastern Time

Presenter: Dr. Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief Financial Officer

Link to webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1362519&tp_key=5ef6204e02

Cantor Virtual Global Healthcare Conference

Date: Thursday, September 17

Time: 2:00 pm Eastern Time

Presenter: Dr. (Read more…) Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief Financial Officer

Link to webcast: https://www.webcaster4.com/Webcast/Page/2495/37404

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus has conducted the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

Contacts

Sasha Damouni Ellis

Vice President, Investor Relations & Corporate Communications

Marinus Pharmaceuticals, Inc.

484-253-6792

[email protected]